Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective

Similar Items

• Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
  od: Bentley, Anthony, i dr.
  Izdano: (2013)
• The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
  od: Kontoghiorghes, George J., i dr.
  Izdano: (2020)
• The Oral Iron Chelator Deferiprone Protects against Iron Overload–Induced Retinal Degeneration
  od: Hadziahmetovic, Majda, i dr.
  Izdano: (2011)
• The Oral Iron Chelator Deferiprone Protects Against Systemic Iron Overload–Induced Retinal Degeneration in Hepcidin Knockout Mice
  od: Song, Delu, i dr.
  Izdano: (2014)
• Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil
  od: WOOD, JOHN C., i dr.
  Izdano: (2006)